Latest research on Dasatinib

Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.

Latest findings

Dasatinib appears to be generally well tolerated, regardless of disease phase, and long-term tolerability data are eagerly awaited. [source, 2005]
Although Dasatinib is still in the initial stages of clinical development, early evidence suggests that its potential impact on the treatment of CML could be substantial. [source, 2005]
Not only could Dasatinib provide a much needed treatment option for patients with imatinib-resistant CML, but also, combined with imatinib, it might prove to be useful in delaying the onset of resistance seen with imatinib monotherapy. [source, 2005]
Furthermore, Dasatinib, in combination with other agents known to be active in CML, may also prove useful for purging the residual leukemic cells that persist even in patients whose disease is controlled by Imatinib. [source, 2005]
The median dose of Imatinib was 400 mg/day, un patient went up to 600 mg and six to 800 mg; when the study was concluded, 4 patients switched to a second generation TYROSINE kinase inhibitor (3 Dasatinib y 1 nilotinib). [source]
We note that both cmp1 and IPA show better selectivity profiles when compared to the clinically approved compounds Sunitinib and Dasatinib. [source]
Kinase-inhibition data for 1 μM inhibitor of each of the clinical and tool compounds STS, Sunitinib, Dasatinib, Imatinib, SB202190, Erlotinib and Gefitinib were provided by Invitrogen based on stock results and not an independent comparison conducted or commissioned by the authors. [source]